132203-70-4 | Cilnidipine

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$7.00	$5.00
50mg	98%	in stock	$9.00	$6.00
100mg	98%	in stock	$11.00	$8.00
250mg	98%	in stock	$15.00	$11.00
1g	98%	in stock	$31.00	$22.00
5g	98%(HPLC)	in stock	$83.00	$59.00
25g	98%(HPLC)	in stock	$186.00	$131.00
100g	98%(HPLC)	in stock	$454.00	$318.00

Description

• Catalog Number: AA46951
• Chemical Name: Cilnidipine
• CAS Number: 132203-70-4
• Molecular Formula: C27H28N2O7
• Molecular Weight: 492.5204
• MDL Number: MFCD00865853
• SMILES: COCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC/C=C/c1ccccc1)C

Computed Properties

• Complexity: 896
• Covalently-Bonded Unit Count: 1
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 11
• Undefined Atom Stereocenter Count: 1
• XLogP3: 4.4

Literature

• Differential modulation of FXR activity by chlorophacinone and ivermectin analogs.

  Toxicology and applied pharmacology 20161215

• Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor.

  Scientific reports 20140101

• Investigation of inclusion complex of cilnidipine with hydroxypropyl-β-cyclodextrin.

  Carbohydrate polymers 20121106

• Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.

  Hypertension research : official journal of the Japanese Society of Hypertension 20121101

• The efficacy and safety of cilnidipine on mild to moderate essential hypertension: a systematic review and meta-analysis of randomized controlled trials in Chinese patients.

  Cardiovascular & hematological disorders drug targets 20120901

• Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.

  Journal of hypertension 20120901

• N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition.

  Journal of pharmacological sciences 20120818

• L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.

  Heart and vessels 20120701

• Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.

  Diabetes research and clinical practice 20120701

• Cilnidipine, an L/N-type calcium channel blocker prevents acquisition and expression of ethanol-induced locomotor sensitization in mice.

  Neuroscience letters 20120411

• Anti-stress effects of cilnidipine and nimodipine in immobilization subjected mice.

  Physiology & behavior 20120320

• Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel.

  Hypertension research : official journal of the Japanese Society of Hypertension 20120101

• Switching to an L/N-type calcium channel blocker shows renoprotective effects in patients with chronic kidney disease: the Kyoto Cilnidipine Study.

  The Journal of international medical research 20120101

• Asymmetric synthesis and biological evaluations of (+)- and (-)-6-dimethoxymethyl-1,4-dihydropyridine-3-carboxylic acid derivatives blocking N-type calcium channels.

  Bioorganic & medicinal chemistry letters 20110601

• Dual actions of cilnidipine in human internal thoracic artery: inhibition of calcium channels and enhancement of endothelial nitric oxide synthase.

  The Journal of thoracic and cardiovascular surgery 20110401

• L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20110401

• Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.

  Cardiovascular therapeutics 20110201

• Effects of an N-type calcium antagonist on angiotensin II-renin feedback.

  American journal of nephrology 20110101

• Effects of the L/N-type calcium channel antagonist cilnidipine on morning blood pressure control and peripheral edema formation.

  Journal of the American Society of Hypertension : JASH 20110101

• Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20110101

• Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.

  Bioorganic & medicinal chemistry 20101115

• The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.

  Heart and vessels 20101101

• A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker.

  Journal of hypertension 20101001

• Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease.

  Expert opinion on investigational drugs 20100901

• Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.

  Journal of hypertension 20100501

• Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial.

  Acta neurologica Scandinavica 20100101

• [Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and autonomic nervous system].

  Clinical calcium 20100101

• [Calcium antagonists: current and future applications based on new evidence. Neuroprotective effect of calcium antagonists].

  Clinical calcium 20100101

• The L/N-type calcium channel blocker, Cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes.

  The Journal of international medical research 20100101

• Effect of cilnidipine on normal to marginally elevated urine albumin-creatinine ratio in asymptomatic non-diabetic hypertensive patients: an exponential decay curve analysis.

  Clinical drug investigation 20100101

• Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20100101

• Oral administration of cilnidipine to patients with hypertensive intracerebral hemorrhage in the acute stage: significance and role of an N-type calcium channel blocker.

  Irish journal of medical science 20091201

• Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.

  British journal of pharmacology 20091101

• Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway.

  Journal of neurochemistry 20091001

• Cardioprotective effect of an L/N-type calcium channel blocker in patients with hypertensive heart disease.

  Journal of cardiology 20091001

• Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker.

  Biological & pharmaceutical bulletin 20091001

• Effects of a dual L/N-type calcium channel blocker cilnidipine on blood pressure, pulse rate, and autonomic functions in patients with mild to moderate hypertension.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20091001

• Efficacy of an L- and N-type calcium channel blocker in hypertensive patients with neurovascular compression of the rostral ventrolateral medulla.

  Hypertension research : official journal of the Japanese Society of Hypertension 20090801

• Comparison of antioxidant activity of cilnidipine and amlodipine.

  Kidney international 20090701

• Histological protection by cilnidipine, a dual L/N-type Ca(2+) channel blocker, against neurotoxicity induced by ischemia-reperfusion in rat retina.

  Experimental eye research 20090501

• Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20090501

• The calcium channel blocker cilnidipine selectively suppresses hypoxia-inducible factor 1 activity in vascular cells.

  European journal of pharmacology 20090315

• Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm.

  American journal of nephrology 20090101

• Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats.

  Arzneimittel-Forschung 20090101

• Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.

  Cardiovascular therapeutics 20090101

• Comparison of the anti-hypertensive effects of the L/N-type calcium channel antagonist cilnidipine, and the L-type calcium channel antagonist amlodipine in hypertensive patients with cerebrovascular disease.

  Internal medicine (Tokyo, Japan) 20090101

• Stress-induced blood pressure elevation in subjects with mild cognitive impairment: effects of the dual-type calcium channel blocker, cilnidipine.

  Geriatrics & gerontology international 20081201

• Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles.

  International heart journal 20081101

• The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels.

  Bioorganic & medicinal chemistry letters 20080901

• Antiproteinuric effects of cilnidipine.

  Kidney international 20080501

• Development of a liquid chromatography/negative-ion electrospray tandem mass spectrometry assay for the determination of cilnidipine in human plasma and its application to a bioequivalence study.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080201

• Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease.

  Kidney international 20071201

• Influence of cilnidipine or nisoldipine on sympathetic activity in healthy male subjects.

  Heart and vessels 20071101

• Renal and vascular protective effects of cilnidipine in patients with essential hypertension.

  Journal of hypertension 20071001

• Determination of cilnidipine, a new calcium antagonist, in human plasma using high performance liquid chromatography with tandem mass spectrometric detection.

  Analytica chimica acta 20070926

• Bedtime administration of cilnidipine controls morning hypertension.

  International heart journal 20070901

• The effect of combination therapy with an L/N-Type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan.

  Hypertension research : official journal of the Japanese Society of Hypertension 20070901

• Assessment of the effects of L- and N-type Ca2+ channel blocking drugs using canine blood-perfused papillary muscle preparations.

  The Tohoku journal of experimental medicine 20070801

• Cardiac effects of L/N-type Ca2+ channel blocker cilnidipine in anesthetized dogs.

  European journal of pharmacology 20070622

• Cilnidipine improves left-ventricular midwall function independently of blood pressure changes in Chinese patients with hypertension.

  Journal of cardiovascular pharmacology 20070101

• Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy.

  Journal of diabetes and its complications 20070101

• Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus. Analysis after switching from cilnidipine to benidipine.

  Arzneimittel-Forschung 20070101

• Effect of cilnidipine on left ventricular function in hypertensive patients as assessed by tissue Doppler Tei index.

  Journal of human hypertension 20060801

• Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.

  Kidney international 20060701

• Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats.

  Biological & pharmaceutical bulletin 20060501

• Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20060501

• Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels.

  Bioorganic & medicinal chemistry letters 20060215

• Cilnidipine, a slow-acting Ca2+ channel blocker, induces relaxation in porcine coronary artery: role of endothelial nitric oxide and [Ca2+]i.

  British journal of pharmacology 20060101

• Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure.

  Hypertension research : official journal of the Japanese Society of Hypertension 20051201

• Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20051101

• Comparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine.

  Heart and vessels 20050501

• Cilnidipine, an N+L-type dihydropyridine Ca channel blocker, suppresses the occurrence of ischemia/reperfusion arrhythmia in a rabbit model of myocardial infarction.

  Hypertension research : official journal of the Japanese Society of Hypertension 20050401

• The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome.

  Nephron. Physiology 20050101

• Prophylactic effects of an N- and L-type Ca2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats.

  Canadian journal of physiology and pharmacology 20050101

• Different effects of L-type and L+N-type calcium channel blockers on hamster cheek pouch venules.

  Journal of cardiovascular pharmacology 20041201

• Cardiovascular effects of an L/N-type Ca2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs.

  Journal of pharmacological sciences 20041001

• Neuroprotective effects of a dual L/N-type Ca(2+) channel blocker cilnidipine in the rat focal brain ischemia model.

  Biological & pharmaceutical bulletin 20040901

• Inhibitory effect of pranidipine on N-type voltage-dependent Ca2+ channels in mice.

  Neuroscience letters 20040826

• Effect of cilnidipine on L- and T-type calcium currents in guinea pig ventricle and action potential in rabbit sinoatrial node.

  Journal of pharmacological sciences 20040701

• Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients.

  Internal medicine (Tokyo, Japan) 20040701

• [Development of desulfated chondroitin sulfate C as a novel chiral selector in capillary electrophoresis and enantioseparation of cilnidipine].

  Se pu = Chinese journal of chromatography 20040701

• The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists.

  Fundamental & clinical pharmacology 20040601

• Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases.

  Hypertension research : official journal of the Japanese Society of Hypertension 20040601

• [Diagnosis of and therapy for renal hypertension].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20040310

• Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients.

  Journal of cardiovascular pharmacology 20040101

• Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension.

  Clinical and experimental hypertension (New York, N.Y. : 1993) 20031101

• [Clinical usefulness of a dual L/N-type Ca2+ channel blocker, cilnidipine, in patients with chronic heart failure: assessment with 123I-MIBG myocardial scintigraphy].

  Kaku igaku. The Japanese journal of nuclear medicine 20031101

• Neuronal Ca2+ channel blocking action of an antihypertensive drug, cilnidipine, in IMR-32 human neuroblastoma cells.

  Hypertension research : official journal of the Japanese Society of Hypertension 20030901

• Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients.

  Hypertension research : official journal of the Japanese Society of Hypertension 20030801

• Cilnidipine as an agent to lower blood pressure without sympathetic nervous activation as demonstrated by iodine-123 metaiodobenzylguanidine imaging in rat hearts.

  Annals of nuclear medicine 20030601

• Effect of cilnidipine on insulin sensitivity in patients with essential hypertension.

  Hypertension research : official journal of the Japanese Society of Hypertension 20030501

• Characterization of Ca2+ current inhibition by cilnidipine using a beta-subunit antisense oligonucleotide.

  European journal of pharmacology 20030411

• Metabolism and metabolic inhibition of cilnidipine in human liver microsomes.

  Acta pharmacologica Sinica 20030301

• Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension.

  Drugs under experimental and clinical research 20030101

• Inhibitory effects of cilnidipine on peripheral and brain N-type Ca2+ channels expressed in BHK cells.

  Neuropharmacology 20020601

• Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C.

  Journal of hypertension 20020501

• N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model.

  Journal of hypertension 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen.

  Journal of hypertension 20020201

• Antisympathetic and hemodynamic property of a dual L/N-type Ca(2+) channel blocker cilnidipine in rats.

  European journal of pharmacology 20020102

• In vivo measurement of 1,4-dihydropyridine receptors in mesenteric arteries of spontaneously hypertensive rats and effect of nifedipine and cilnidipine.

  Biological & pharmaceutical bulletin 20020101

• Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine.

  Hypertension research : official journal of the Japanese Society of Hypertension 20011101

• Reduction of white coat effect by cilnidipine in essential hypertension.

  American journal of hypertension 20011001

• Effects of the L- and N-type calcium channel blocker cilnidipine on growth of vascular smooth muscle cells from spontaneously hypertensive rats.

  Journal of cardiovascular pharmacology 20010901

• Effects of cilnidipine on muscle fiber composition, capillary density and muscle blood flow in fructose-fed rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20010901

• Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis.

  Hypertension research : official journal of the Japanese Society of Hypertension 20010701

• Effects of cilnidipine on nitric oxide and endothelin-1 expression and extracellular signal-regulated kinase in hypertensive rats.

  European journal of pharmacology 20010622

• Effect of cilnidipine on left ventricular diastolic function in hypertensive patients as assessed by pulsed Doppler echocardiography and pulsed tissue Doppler imaging.

  Japanese circulation journal 20010401

• State-dependent inhibition of L-type Ca2+ channels in A7r5 cells by cilnidipine and its derivatives.

  Japanese journal of pharmacology 20010301

• Effects of a dual L/N-type Ca(2+) channel blocker cilnidipine on neurally mediated chronotropic response in anesthetized dogs.

  European journal of pharmacology 20010209

• [Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 19990501

• Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard.

  Journal of cardiovascular pharmacology 19980801

• Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons.

  The Journal of pharmacology and experimental therapeutics 19970301